Rashin ciwon zuciya tare da raguwar raguwar fitarwa (HFrEF) babban nau'in ciwon zuciya ne, kuma binciken HF na kasar Sin ya nuna cewa kashi 42 cikin 100 na raunin zuciya a kasar Sin HFrEF ne, ko da yake akwai nau'o'in magunguna da yawa na HFrEF kuma sun rage hadarin. na mutuwa da kuma asibiti ga ciwon zuciya zuwa wani matsayi. Duk da haka, marasa lafiya suna cikin haɗari mai yawa na ciwon zuciya mai maimaitawa yana kara muni, mace-mace ya kasance a kusa da 25% kuma tsinkaye ya kasance matalauta. Sabili da haka, har yanzu akwai buƙatar gaggawa don sababbin magungunan warkewa a cikin jiyya na HFrEF, da kuma Vericiguat, wani labari mai soluble guanylate cyclase (sGC) stimulator, an yi nazari a cikin binciken VICTORIA don tantance ko Vericiguat zai iya inganta hangen nesa na marasa lafiya tare da HFrEF. Binciken yana da ƙungiyoyi masu yawa, bazuwar, rukuni-rukuni-daidaitacce, mai sarrafa wuribo, makafi biyu, abin da ya faru, binciken sakamako na asibiti na III. An gudanar da shi a karkashin kulawar cibiyar VIGOR da ke kasar Kanada tare da hadin gwiwar Cibiyar Nazarin Clinical Research ta Duke, cibiyoyi 616 na kasashe da yankuna 42 da suka hada da Turai da Japan da Sin da Amurka sun shiga cikin binciken. An karrama sashen ilimin zuciya na mu don shiga. Jimillar marasa lafiya 5,050 tare da ciwon zuciya na yau da kullun shekaru ≥18 shekaru, NYHA aji II-IV, EF <45%, tare da haɓakar peptide natriuretic peptide (NT-proBNP) a cikin kwanaki 30 kafin bazuwar, kuma waɗanda aka kwantar da su a asibiti don gazawar zuciya. a cikin watanni 6 kafin bazuwar ko kuma an yi amfani da diuretics a cikin jini don gazawar zuciya a cikin watanni 3 kafin bazuwar. binciken, duk masu karɓar ESC, AHA / ACC, da ƙayyadaddun ƙa'idodin yanki / yanki sun ba da shawarar daidaitattun kulawa. An ba da izini ga marasa lafiya a cikin rabo na 1: 1 zuwa ƙungiyoyi biyu kuma an ba suVericiguat(n=2526) da placebo (n=2524) a saman daidaitaccen jiyya, bi da bi.
Mahimmin ƙarshen binciken shine ƙayyadaddun ƙayyadaddun ƙarshen mutuwar cututtukan zuciya ko rashin lafiyar zuciya na farko; Ƙarshen ƙarshe na biyu sun haɗa da sassa na ƙarshen ƙarshen farko, na farko da na gaba na ciwon zuciya na asibiti (al'amuran farko da na yau da kullum), ƙayyadaddun ƙayyadaddun abubuwan da ke haifar da mutuwa ko rashin ciwon zuciya a asibiti, da kuma mutuwa duka. A matsakaicin matsakaici na watanni 10.8, an sami raguwar dangi na 10% a farkon ƙarshen mutuwar zuciya da jijiyoyin jini ko kuma rashin lafiyar zuciya na farko a cikin ƙungiyar Vericiguat idan aka kwatanta da ƙungiyar placebo.
Binciken ƙarshen ƙarshen na biyu ya nuna raguwa mai mahimmanci a cikin asibiti na rashin lafiyar zuciya (HR 0.90) da kuma raguwa mai yawa a cikin ƙarshen ƙarshen ƙarshen mutuwar ko ciwon zuciya (HR 0.90) a cikin ƙungiyar Vericiguat idan aka kwatanta da ƙungiyar placebo.
Sakamakon binciken ya nuna cewa ƙari naVericiguatdon daidaitaccen magani na rashin ciwon zuciya yana rage abin da ya faru na kwanan nan na abubuwan da suka faru na rashin ciwon zuciya da kuma rage haɗarin haɗuwar ƙarshen mutuwar zuciya ko asibiti don ciwon zuciya a cikin marasa lafiya tare da HFrEF. Ƙarfin Vericiguat don rage haɗarin haɗakar ƙarshen ƙarshen mutuwar zuciya ko rashin lafiyar zuciya a cikin marasa lafiya tare da ciwon zuciya mai haɗari yana ba da sabuwar hanyar warkewa don ciwon zuciya kuma yana buɗe sababbin hanyoyi don bincike na gaba na cututtukan zuciya. A halin yanzu ba a yarda da Vericiguat don talla ba. Amintaccen, inganci da ƙimar ƙimar magani har yanzu yana buƙatar ƙarin gwaji a kasuwa.
Lokacin aikawa: Fabrairu-09-2022